Abstract：
Anabolic bone agents, such as parathyroid hormone receptor agonists (teriparatide and abaloparatide) and sclerostin-inhibiting monoclonal antibody (romosozumab), are superior at preventing clinically significant fractures and/or vertebral fractures in women with and without severe osteoporosis compared with bisphosphonates.
摘要：
合成代谢骨剂，如甲状旁腺激素受体激动剂（特立帕肽和阿巴罗帕拉肽）和硬化素抑制单克隆抗体（romosozumab），与双膦酸盐相比，有和没有严重骨质疏松症的女性在预防临床上明显的骨折和/或椎骨骨折方面具有优势。
